Prospective, Single-arm, Multicenter Clinical Study of Hepatic Artery Infusion Chemotherapy With Donafenib for Adjuvant Treatment of HCC Patients With High Risk of Recurrence After Hepatectomy

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Donafenib (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
Indications Liver cancer
Focus Therapeutic Use

04 Jun 2024 Results(n=18) exploring the efficacy and safety of adjuvant HAIC plus the novel multikinase inhibitor donafenib in HCC with solitary tumor greater than or equal to 5 cm and MVI, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
21 Jun 2023 Planned initiation date changed from 1 Nov 2021 to 1 Jul 2023.
22 Sep 2021 Planned initiation date changed from 1 Aug 2021 to 1 Nov 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com